ROCKVILLE, Md., Aug. 1, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTC:RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue protection, repair, and regeneration, announced that, pursuant to the company's consent solicitation dated July 11, 2023, holders of 48.5% of the Company's outstanding stock have voted to date, with 94% voting in favor of the proposed reverse stock split. However, the Company must receive consents from the holders of a majority of the outstanding shares to proceed with the planned reverse stock split. Accordingly, the Company is continuing to solicit consents from stockholders.
Read more at prnewswire.comRegeneRx To Extend Consent Solicitation Vote
PR Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/AI%20(artificial%20intelligence)/Businessman%20touching%20the%20brain%20working%20of%20Artificial%20Intelligence%20(AI)%20Automation%20by%20Suttiphong%20Chandaeng%20via%20Shutterstock.jpg)
/Nvidia%20logo%20by%20Konstantin%20Savusia%20via%20Shutterstock.jpg)
/Broadcom%20Inc%20logo%20on%20building-by%20Poetra_%20RH%20via%20Shutterstock.jpg)
/An%20image%20of%20a%20Tesla%20humanoid%20robot%20in%20front%20of%20the%20company%20logo%20Around%20the%20World%20Photos%20via%20Shutterstock.jpg)
